Neutralizing antibody titers conferring protection to macaques from a Simian/human immunodeficiency virus challenge using the TZM-bl assay

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 89-98

  Willey, Ronald ^a   Nason, Martha C ^a   Nishimura, Yoshiaki ^a   Follmann, Dean A ^a   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL ASSAY; CONTROLLED STUDY; INFECTION RESISTANCE; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS; VIRUS NEUTRALIZATION; VIRUS TYPING;

ANIMALS; ANTIBODIES, NEUTRALIZING; HIV; HIV ANTIBODIES; HUMANS; INHIBITORY CONCENTRATION 50; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 76449108010     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0144     Document Type: Article

References (46)

1. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292(5514):69-74.
2. Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia andpreventionof clinicalAIDS inrhesusmonkeysbycytokineaugmented DNAvaccination. Science 2000;290(5491):486-492.
3. Letvin NL, Mascola JR, Sun Y, et al.: Preserved CD4+central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006;312(5779):1530-1533.
4. Wilson NA, Reed J, Napoe GS, et al.: Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006;80(12): 5875-5885.
5. Casimiro DR, Wang F, Schleif WA, et al.: Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005;79(24): 15547-15555.
6. Liu J, O'Brien KL, Lynch DM, et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009;457(7225):87-91.
7. Ourmanov I, Brown CR, Moss B, et al.: Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000; 74(6):2740-2751.
8. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283(5403):857-860.
9. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity. Nature 2002;415(6869):331-335.
10. Barnett SW, Srivastava IK, Kan E, et al.: Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008;22(3):339-348.
11. Cho MW, Kim YB, Lee MK, et al.: Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001;75(5):2224-2234.
12. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6(2):200-206.
13. Mascola JR, Lewis MG, Stiegler G, et al.: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73(5):4009-4018.
14. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6(2):207-210.
15. Nishimura Y, Igarashi T, Haigwood N, et al.: Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002;76(5):2123-2130.
16. Parren PW, Marx PA, Hessell AJ, et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75(17): 8340-8347.
17. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5(2):204-210.
18. Karlsson-Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, and Wyatt RT: The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008;6(2):143-155.
19. Frost SD, Wrin T, Smith DM, et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005;102(51):18514-18519.
20. Richman DD, Wrin T, Little SJ, and Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100(7):4144-4149.
21. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422(6929):307-312.
22. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5(3):233-236.
23. Li Y, Migueles SA, Welcher B, et al.: Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007;13(9):1032-1034.
24. Scheid JF, Mouquet H, Feldhahn N, et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009;458(7238):636-640.
25. Brown BK, Wieczorek L, Sanders-Buell E, et al.: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008;375(2):529-538.
26. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266(5187):1024-1027.
27. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79(16):10108-10125.
28. Polonis VR, Brown BK, Rosa Borges A, et al.: Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008;375(2):315-320.
29. Willey RL, Shibata R, Freed EO, Cho MW, and Martin MA: Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type1 envelopeproducedfrominfectedprimaryT- lymphocyte and macrophage cultures. J Virol 1996;70(9):6431-6436.
30. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, and Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996;70(6): 3724-3733.
31. Reed LJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-497.
32. Shibata R, Maldarelli F, Siemon C, et al.: Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing. J Infect Dis 1997;176(2):362-373.
33. Shibata R, Hoggan MD, Broscius C, et al.: Isolation and characterization of a syncytium-inducing, macrophage/ T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol 1995;69(7):4453-4462.
34. Finney DJ: Probit Analysis, 3d ed. Cambridge University Press, Cambridge, England, 2007.
35. Cox DR and Hinkley DV: Theoretical Statistics. Chapman & Hall, London, England, 1974.
36. Binley JM, Lybarger EA, Crooks ET, et al.: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008;82(23):11651-11668.
37. Kraft Z, Derby NR, McCaffrey RA, et al.: Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 2007;81(12):6402-6411.
38. Morner A, Douagi I, Forsell MN, et al.: Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 2009;83(2):540-551.
39. Louder MK, Sambor A, Chertova E, et al.: HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005;339(2):226-238.
40. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, and Trkola A: HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 2009;23(13):1659-1667.
41. Forthal DN, Landucci G, and Daar ES: Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001;75(15):6953-6961.
42. Forthal DN, Landucci G, Haubrich R, et al.: Antibodydependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999; 180(4):1338-1341.
43. Gomez-Roman VR, Patterson LJ, Venzon D, et al.: Vaccineelicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174(4):2185-2189.
44. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449(7158):101-104.
45. Blish CA, Dogan OC, Derby NR, et al.: Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 2008;82(24): 12094-12103.
46. Trkola A, Kuster H, Rusert P, et al.: In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers. J Virol 2008;82(3):1591-1599.